Hematological Neoplasms

Recently, The Lancet Haematology published the results of a phase 1 clinical trial indicating that CD30-targeted CAR-T cell therapy (ATLCAR.CD30) has the potential to serve as a consolidation treatment for high-risk Hodgkin lymphoma patients after autologous HSCT.

On May 15, 2024, the U.S. Food and Drug Administration (FDA) granted accelerated approval for an immunotherapy treatment for follicular lymphoma.

Primary central nervous system lymphoma (PCNSL) is a central nervous system-confined non-Hodgkin lymphoma (NHL), with the pathological diagnosis being mainly diffuse large B-cell lymphoma.

On May 30, 2024, Bristol Myers Squibb announced that the U.S. FDA has approved the expanded indication of its CAR-T therapy Breyanzi (lisocabtagene maraleucel; liso-cel) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including those who have been previously treated with a Bruton’s tyrosine kinase (BTK) inhibitor.

In January 2022, Bristol Myers Squibb (BMS) announced the pre-specified interim analysis data from the pivotal Phase 3 TRANSFORM study (NCT03575351).

On Thursday, May 31, 2024, the U.S. Food and Drug Administration (FDA) approved Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), making this CD19-targeted cellular therapy the broadest approved for B-cell malignancies.

Approved Indications: Relapsed/Refractory Large B-cell Lymphoma, Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL), Follicular Lymphoma, Mantle Cell Lymphoma.

On May 16, 2024, the U.S. Food and Drug Administration (FDA) announced accelerated approval for the expanded indication of Breyanzi, Bristol Myers Squibb’s CAR-T cell therapy, for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy.

Breyanzi was approved by the U.S. FDA on February 5, 2021, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy developed by the American pharmaceutical company Bristol Myers Squibb (BMS) for the first-line treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after treatment.

In the ever-evolving landscape of cancer treatment, CAR-T (Chimeric Antigen Receptor T-cell) therapy has emerged as a game-changer, offering hope to patients with relapsed or refractory hematological malignancies.